An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis

Phase 2 Completed 87 enrolled Incyte Corporation

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a study of itacitinib (INCB039110) in patients with myelofibrosis. This study will evaluate safety and efficacy parameters of itacitinib (INCB039110).

Timeline

Start: 2012-07-16
Primary completion: 2013-12-31
Completion: 2021-06-29

Publications

Mascarenhas JO, Talpaz M, Gupta V, Foltz LM, Savona MR, Paquette R, Turner AR, Coughlin P, Winton E, Burn TC, O'Neill P, Clark J, Hunter D, Assad A, Hoffman R, Verstovsek S. Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Haematologica. 2017 Feb;102(2):327-335. doi: 10.3324/haematol.2016.151126. Epub 2016 Oct 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Itacitinib	Small molecule	100 mg	Oral
Subject	Itacitinib	Small molecule	200 mg	Oral
Subject	Itacitinib	Small molecule	300 mg	Oral
Subject	Itacitinib	Small molecule	400 mg	Oral
Subject	Itacitinib	Small molecule	600 mg	Oral

An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis

Summary

Timeline

Publications

Drugs

Indications